Delivery of miR-200c-3p Using Tumor-Targeted Mesoporous Silica Nanoparticles for Breast Cancer Therapy

therapy Lung Neoplasms microRNA Mesoporous silica nanoparticles QUIMICA INORGANICA targeted delivery MicroRNA Silicon Dioxide 3. Good health Gene Expression Regulation, Neoplastic Mice MicroRNAs breast cancer Breast cancer QUIMICA ORGANICA Cell Movement Cell Line, Tumor breast cancer, mesoporous silica nanoparticles, microRNA, targeted delivery, therapy Animals Nanoparticles Female Therapy Targeted delivery mesoporous silica nanoparticles Cell Proliferation
DOI: 10.1021/acsami.3c07541 Publication Date: 2023-08-07T20:45:06Z
ABSTRACT
Despite advances in breast cancer treatment, it remains the leading cause of cancer-related death in women worldwide. In this context, microRNAs have emerged as potential therapeutic targets but still present some limitations for in vivo applications. Particularly, miR-200c-3p is a well-known tumor suppressor microRNA that inhibits tumor progression and metastasis in breast cancer through downregulating ZEB1 and ZEB2. Based on the above, we describe the design and validation of a nanodevice using mesoporous silica nanoparticles for miR-200c-3p delivery for breast cancer treatment. We demonstrate the biocompatibility of the synthesized nanodevices as well as their ability to escape from endosomes/lysosomes and inhibit tumorigenesis, invasion, migration, and proliferation of tumor cells in vitro. Moreover, tumor targeting and effective delivery of miR-200c-3p from the nanoparticles in vivo are confirmed in an orthotopic breast cancer mouse model, and the therapeutic efficacy is also evidenced by a decrease in tumor size and lung metastasis, while showing no signs of toxicity. Overall, our results provide evidence that miR-200c-3p-loaded nanoparticles are a potential strategy for breast cancer therapy and a safe and effective system for tumor-targeted delivery of microRNAs.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (67)
CITATIONS (22)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....